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Abstract
Background—Thiazolidinediones (TZD) were reported to protect against ischemia-reperfusion
(I/R) injury. Their protective actions are considered to be PPAR-γ (peroxisome proliferator-
activated receptor γ)-dependent. However, it is unclear how PPAR-γ activation confers resistance
to I/R.
Methods and Results—We evaluated the effects of rosiglitazone or PPAR-γ overexpression on
cerebral infarction in a rat model and investigated the anti-apoptotic actions in N2-A
neuroblastoma cell model. Rosiglitazone or PPAR-γ overexpression significantly reduced infarct
volume. The protective effect was abrogated by PPAR-γ siRNA. In mice with knockin of a PPAR-
γ domain negative mutant, infarct volume was enhanced. Proteomic analysis reveals that brain
14-3-3ε was highly upregulated in rats treated with rosiglitazone. 14-3-3ε upregulation was
abrogated by PPAR-γ siRNA or antagonist. Promoter analysis and chromatin immunoprecipitation
reveal that rosiglitazone induced PPAR-γ binding to specific regulatory elements on 14-3-3ε
promoter and thereby increased 14-3-3ε transcription. 14-3-3ε siRNA abrogated the anti-apoptotic
actions of rosiglitazone or PPAR-γ overexpression while 14-3-3ε recombinant proteins rescued
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brain tissues and N2-A cells from ischemia-induced damage and apoptosis. Elevated 14-3-3ε
enhanced binding of phosphorylated Bad, and protected mitochondrial membrane potential.
Conclusions—Ligand-activated PPAR-γ confers resistance to neuronal apoptosis and cerebral
infarction by driving 14-3-3ε transcription. 14-3-3ε upregulation enhances sequestration of
phosphorylated Bad and thereby suppresses apoptosis.
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Introduction
Peroxisome proliferator-activated receptor-γ (PPAR-γ), a member of the PPAR nuclear
receptor family, is a ligand-activated transcription factor that regulates diverse biological
activities and plays major roles in important human diseases such as diabetes, metabolic
syndrome and atherosclerosis (1). Several classes of PPAR-γ ligands have been identified.
Naturally occurring fatty acid derivatives such as 15 deoxy-Δ12, 14 prostaglandin J2 (15d-
PGJ2) binds and activates PPAR-γ and is thought to mediate the anti-inflammatory action of
PPAR-γ (2, 3). Synthetic PPAR-γ ligands such as thiazolidinedione (TZD) are clinically
efficacious in treating type 2 diabetes (4). Ligand-activated PPAR-γ forms heterodimers
with retinoid X receptor which binds PPAR response elements (PPRE) situated at the
promoter region of target genes and regulates the gene expression (1). Extensive
investigations have reported that ligand-activated PPAR-γ suppresses pro-inflammatory
genes at the transcriptional level (5-8). The anti-inflammatory action of PPAR-γ ligands was
considered to contribute to tissue protection. Rosiglitazone was reported to protect against
ischemia-reperfusion (I/R) induced myocardial damage while troglitazone and pioglitazone
protect against cerebral infarction in a rat I/R stroke model (9-11). We have previously
reported that 15d-PGJ2 was effective in reducing cerebral infarct volume in a rat model (12).
Our previous in vitro data suggest that 15d-PGJ2 and TZDs such as rosiglitazone protect
neurons from oxidant-induced apoptosis (12). The purpose of this study was to evaluate the
effects of rosiglitazone and PPAR-γ overexpression on neural apoptosis and to identify the
downstream effector molecules. The results show that rosiglitazone and PPAR-γ
overexpression protected against I/R damage in a rat stroke model and in mice with knockin
of a PPAR-γ dominant negative mutant. Proteomic analysis of ischemic rat brain identified
14-3-3ε to be highly elevated in rosiglitazone-treated rats. Results from animal and cell
experiments reveal that 14-3-3ε was upregulated by ligand-activated PPAR-γ at the
transcriptional level. Knockdown of 14-3-3ε with RNAi abrogated the protective effect of
rosiglitazone and PPAR-γ while ectopic expression of 14-3-3ε or infusion of 14-3-3ε
proteins rescued brains from infarction and neuronal cells from ischemic damage.
Methods
Animal Models
The rat focal cerebral ischemia-reperfusion model was described previously (13, 14) (see
supplemental materials). The PPAR-γ P465L mutant mice were prepared as previously
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described (15). In brief, the inbred foundation colony was maintained by breeding
heterozygous P465L mutant mice with inbred 129/SvEv mice. The production colony for
experiments was maintained by breeding heterozygous P465L knockin mice on the 129/
SvEv genetic background with C57BL/6J mice. This produced both wild type and
heterozygous P465L knockin mice on the same inbred genetic background (129/SvEv X
C57BL/6J F1). Littermate wild type serves as control mice.
Oxygen-glucose deprivation (OGD) cell model
Murine N2-A neuroblastoma cells (American Type Culture Collection) grown to 70%
confluence were treated with rosiglitazone (Cayman) alone or in combination with
GW9662, washed with deoxygenated glucose-free Hanks’ balanced salt solution, and
transferred to an anaerobic chamber (Model 1025, Forma Scientific) containing a gas
mixture of 5% CO2, 10% H2, 85% N2, and 0.02% to 0.1% O2 (16, 17) for 3 h. After OGD,
N2-A cells were cultured in glucose-containing Hanks’ balanced salt solution under the
normoxic condition in a 5% CO2 incubator for various time periods.
Transient transfection
Mouse PPAR-γ1 expression plasmid was prepared by cloning PPAR-γ1 into pcDNA3.1+
vector. Specific PPAR-γ small interfering RNA (siRNA) and scrambled RNA (scRNA)
were purchased from Ambion. 14-3-3ε expression plasmid was prepared as previously
described (18). In brief, the complete coding sequence of 14-3-3ε was amplified by PCR and
cloned into pcDNA3.1+ vector (Invitrogen). Specific 14-3-3ε siRNA was purchased from
Santa Cruz. Lipofectamine 2000 (Invitrogen) was used as a transfection carrier according to
manufacturer's instructions (see supplemental materials).
Reporter Assay
PPRE-reporter construct, acyl-CoA oxidase (ACO)-Luc, was prepared by cloning luciferase
into an ACO vector, which contains 4 PPAR response elements (PPREs) and a minimal
cytomegalovirus promoter. pCMV-β-galactosidase (β-Gal) plasmid was used as an internal
control of transfection. For cloning 14-3-3ε promoter, a 1.6-kb (–1625 to +24) 5'-flanking
region of human genomic sequence was amplified by PCR and cloned into pGL3 luciferase
reporter (18). Transfection was performed as previously described (18) and described in
supplemental materials.
Western Blot and Immunoprecipitation Analysis
Analysis of proteins in the cortex and N2-A cells by Western blotting was performed as
described previously (12). Immunoprecipitation was performed as described (18). (See
supplemental materials.)
Flow Cytometry
Flow cytometry was employed to analyze apoptosis and mitochondria membrane potential
(see supplemental materials).
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Intraventricular Injection of rosiglitazone, GW9662, PPAR-γ siRNA and 14-3-3ε siRNA
The procedure was performed as previously described (12). Briefly, anesthetized rats were
placed in a stereotaxic apparatus; 50 ng (0.14 nmol) rosiglitazone, 165 ng (0.58 nmol)
GW9662 or 0.1-2 nmol siRNA in 10 μL volume were injected into the right lateral ventricle
at 2 μL/min at the following coordinates: Anterior, 2.5 mm caudal to bregma; Right, 2.8 mm
lateral to midline; and Ventral, 3.0 mm ventral to dural surface. Periodic confirmation of
proper placement of the needle was performed with infusionof fast green. Rosiglitazone,
PPARγ siRNA or control was injected into the lateral ventricle for 24 h immediately after
the 30 min transient occlusion. The extent of PPAR-γ knockdown by siRNA was quantified
by RT-PCR at 24 h after reperfusion.
Intraventricular Infusion of PPAR-γ and 14-3-3ε recombinant proteins
Rats were anesthetized with chloral hydrate (360 mg/kg, i.p.). The brain infusion cannula
was inserted into the right ventricle of the brain at a point located 2 mm lateral and 2 mm
posterior to the bregma, and at a depth of 3 mm from the cortical surface. The osmotic pump
(Alzet 1007D) with brain infusion kit ∥ was installed in subcutaneous pocket on the lateral
back of the rats. An instant adhesive gel (Loctite 454) was used to affix the infusion cannula
to the skull, and wound was closed with sutures. Recombinant PPAR-γ (Cayman), His-
tagged 14-3-3ε (Cayman) or vehicle was infused continuously for 72 h (1.2 μg/day at a rate
of 0.5 μL/h) via the osmotic pump prior to I/R.
RNA isolation, reverse transcription (RT) and polymerase chain reaction (PCR)
Total RNA isolation and RT-PCR amplication were performed as previously described (12)
(see supplemental materials).
Two-dimensional gel electrophoresis (2-DGE) and mass spectrometry
Rat brain was homogenized and 130 μg of the supernatant proteins were subjected to 2-DGE
analysis (see supplemental materials). Gels were stained and analyzed by ImageMaster 2-D
analysis software. The gel images were normalized according to the total quantity in the
analysis set. An expression intensity ratio larger than 2.0 was considered to be a significant
change. Spots with significant changes were removed and analyzed by liquid
chromatography and tandem mass spectrometry (LC-MS/MS) (see supplemental materials).
Chromatin Immunoprecipitation (ChIP) assay
ChIP assay was performed as previously described (18,19) (see supplemental materials).
Statistical Analysis
Analysis of variance (ANOVA) was used to compare the expression of proteins or infarct
volumes. The level of significance for differences between groups was further analyzed with
post-hoc Fisher's protected t tests by GB-STAT 5.0.4 (Dynamic Microsystem, Inc, Silver
Springs, Md). P<0.05 was considered significant.
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Results
Rosiglitazone-PPAR-γ protects brain against I/R injury in a rat model
To evaluate the in vivo neuroprotective effect, rosiglitazone was injected intraventricularly
immediately after 30-min ischemia and the infarct volume at the ipsilateral brain was
measured 24 h later. There was no significant difference in physiologic variables between
vehicle control and rosiglitazone-treated groups (supplemental Table S1). Rosiglitazone at
0.5 to 150 ng significantly reduced the infarct volume. The maximal reduction occurred at
50 ng while at higher concentrations (300 & 500 ng) it no longer had protective effect (Fig.
1a). We used 50 ng of rosiglitazone in the remaining studies. Infusion of rosiglitazone 2 h
after reperfusion was still effective in reducing infarct volume (Fig. 1b). The protective
effect of rosiglitazone was blocked by GW9662 (Fig. 1c). Intraventricular injection of a
PPAR-γ siRNA for 24 h suppressed PPAR-γ mRNA in normal brain tissues (Fig. S1) as
well as in ischemic brain tissues when compared to scRNA injection (Fig. 1d). The PPAR-γ
siRNA injection immediately after the 30-min ischemia concentration-dependently
abrogated the protective effect of rosiglitazone while scRNA had no effect (Fig. 1e).
Intraventricular infusion of PPAR-γ proteins (5μg) for 72 h before I/R reduced the infarct
volume by > 60% when compared to control (Fig. 1f). The essential role of PPAR-γ was
further evaluated in mice with heterozygous knockin of a PPAR-γ dominant negative
mutant, P465L (L/+). Wild-type or L/+ mice were subjected to 30 min ischemia followed by
24 h reperfusion. Compared to wild-type mice with a mean infarct volume of 8 mm3, the
infarct volume in L/+ mice was increased by about 80% (Fig. 1g).
The anti-apoptotic effect of rosiglitazone was evaluated in ischemic rat brain tissues.
Rosiglitazone injection immediately after the 30-min ischemia reduced cleaved PARP and
activated caspase 3 and caspase 9 when compared to vehicle (DMSO) (Fig. 2a). PPAR-γ
siRNA abrogated the anti-apoptotic action of rosiglitazone (Fig. 2a), while infusion of
recombinant PPAR-γ proteins suppressed the apoptotic changes (Fig. 2b). These results
indicate that rosiglitazone protects brain from I/R-induced apoptosis.
Proteomic analysis identifies 14-3-3ε upregulation by rosiglitazone in ischemic brain
To identify proteins important in the rosiglitazone-PPAR-γ signaling pathway, we analyzed
ischemic brain tissues by proteomics. Rats were subjected to a 30-min transient ischemia.
Rosiglitazone or vehicle was administered right after ischemia for 24 h. Brain was isolated,
homogenized and proteins were analyzed by 2-DGE. A spot with a very large increase in
density in rosiglitazone vs. control (5.5-fold) was identified (Fig. 3a). The spot was removed
and the protein identity was analyzed by LC-MS/MS. The protein matches 14-3-3ε. Western
blot analysis confirmed that rosiglitazone pretreatment restored the suppressed 14-3-3ε
proteins in ischemic brain tissues (Fig. 3b). To determine whether 14-3-3ε upregulation in
brain tissues is PPAR-γ dependent, we analyzed 14-3-3ε proteins in the ipsilateral brain 24 h
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after infusion of rosiglitazone or DMSO. Rosiglitazone increased 14-3-3ε proteins by >3
fold (Fig. 3c). This increase was inhibited by PPAR-γ siRNA. Infusion of recombinant
PPAR-γ proteins also increased 14-3-3ε (Fig. 3d). Furthermore, 14-3-3ε proteins in L/+
mouse brain were reduced by ~50% when compared to wild-type brain (Fig. 3e).
Rosiglitazone upregulates 14-3-3ε transcription
To elucidate the mechanism by which 14-3-3ε expression is upregulated, we employed N2-
A neuroblastoma cells as a model. Cells were incubated with rosiglitazone at increasing
concentrations and 14-3-3ε proteins were analyzed 24 h later. Rosiglitazone concentration-
dependently increased 14-3-3ε proteins (Fig. 4a). This increase was blocked by GW9662
(Fig. 4b) or PPAR-γ siRNA (Fig 4c). Transfection with PPAR-γ plasmids for 24 h increased
14-3-3ε proteins in a concentration-dependent manner (Fig. 4d).
We have previously cloned a ~1.6 kb 5’-flanking region of 14-3-3ε gene which harbors
three PPRE between -1348 and -1625 (18). To determine the involvement of PPREs in
rosiglitazone-induced 14-3-3ε upregulation, we transfected N2-A cells with this promoter
fragment (p1625-LUC) or a 5’-deletion mutant in which the PPREs were removed (p1348-
LUC). Rosiglitazone increased the p1625 promoter activity in a concentration-dependent
manner (Fig. S2a), but did not increase p1348 activity (Fig. 4e). Overexpressoin of PPAR-γ
by transient transfection of PPAR-γ plasmid (Fig. S2b) also increased the p1625 promoter
activity (Fig. S2c) which was abrogated when the PPRE region was deleted (Fig. 4f). ChIP
assays show that rosiglitazone induced binding of PPAR-γ but not PPAR-β/δ to PPRE-
harboring region between -1554 and -1854 of 14-3-3ε promoter despite expressions of both
PPAR proteins in this cell line (data not shown) (Fig. 4g). These results indicate that
rosiglitazone selectively induced binding of PPAR-γ to 14-3-3ε PPREs, thereby activating
14-3-3ε promoter and upregulating 14-3-3ε protein expression.
14-3-3ε protects brain from I/R injury
To determine the role of 14-3-3ε upregulation in controlling I/R induced infarction, we
infused rosiglitazone with 14-3-3ε siRNA or control scRNA immediately after the 30-min
ischemia. Reduction of the infarct volume by rosiglitazone was abrogated by 14-3-3ε siRNA
in a concentration-dependent manner (Fig. 5a). 14-3-3ε mRNA in siRNA treated brain was
reduced when compared to scRNA control (Fig. 5a, inset). Conversely, overexpression of
14-3-3ε (Fig. 5b, inset) by infusion of recombinant 14-3-3ε proteins for 72 h before I/R
reduced infarct volume in a dose-dependent fashion (Fig. 5b).
Rosiglitazone prevents neuronal apoptosis via PPAR-γ to 14-3-3ε pathway
To confirm that ligand-activated PPAR-γ prevents neuronal apoptosis via 14-3-3ε
upregulation, N2-A cells were subjected to OGD for 3 h followed by reoxygenation for 24 h
(H3R24) and cells with apoptosis were analyzed by flow cytometry. OGD (H3R24)
increased percentage of apoptotic cells which was reduced by pretreatment with
rosiglitazone (Fig. 6a). The effect of rosiglitazone was abrogated by GW9662 (Fig. 6a).
OGD enhanced PARP cleavage and caspase 3 and 9 activation which were suppressed by
rosiglitazone and reversed by GW9662 (Fig. 6b). To ascertain the anti-apoptotic action of
ligand-activated PPAR-γ, we transfected N2-A with PPAR-γ siRNA and analyzed apoptotic
Wu et al. Page 6






















changes. PPAR-γ in N2-A cells was functional as evidenced by activation by rosiglitazone
of a PPAR promoter construct, ACO-(PPRE)4-Luc which was inhibited by GW9662 (Fig.
S3a). PPAR-γ siRNA which suppressed PPAR-γ proteins (Fig. S3b) and mRNA (Fig. S3c)
abrogated the ACO-(PPRE)4 promoter activity induced by rosiglitazone (Fig. S3d). The
anti-apoptotic effect of rosiglitazone was abrogated by PPAR-γ siRNA but not scRNA (Fig.
6c). Treatment of N2-A with PPAR-γ vectors reduced apoptotic cells (Fig. 6d). The results
are consistent with inhibition of apoptosis by rosiglitazone via PPAR-γ.
To confirm that the neuroprotective effect of rosiglitazone and PPAR-γ overexpression is
mediated by 14-3-3ε, we evaluated the effect of rosiglitazone on 14-3-3ε levels in OGD-
injured N2-A. 14-3-3ε proteins were detected in N2-A which was enhanced by rosiglitazone
(Fig. 7a). 14-3-3ε proteins were suppressed in OGD -treated cells which were restored by
rosiglitazone but the rescue was prevented by GW9662 (Fig. 7a). Similarly, restoration of
14-3-3ε proteins under OGD insults was abrogated by PPAR-γ siRNA but not scRNA (Fig.
7b). Conversely, reduction of 14-3-3ε proteins in OGD-treated cells was attenuated by
PPAR-γ transfection (Fig. 7c). These results suggest that rosiglitazone or PPAR-γ
overexpression prevents 14-3-3ε suppression by OGD insults.
To determine if 14-3-3ε upregulation is essential for the anti-apoptotic action of
rosiglitazone and PPAR-γ, we treated cells with rosiglitazone in the presence of 14-3-3ε
siRNA or control scRNA and subjected them to OGD (H3R24). 14-3-3ε siRNA
concentration-dependently suppressed 14-3-3ε proteins in N2-A (Fig. S4a). The anti-
apoptotic effect of rosiglitazone and PPAR-γ overexpression was abrogated by 14-3-3ε
siRNA but not scRNA (Fig. 7d and 7e). We next determined if 14-3-3ε overexpression
rescues cells from OGD-induced apoptosis. 14-3-3ε overexpression by transient transfection
(Fig. S4b) significantly reduced OGD-induced apoptotic cells (Fig. 7f).
Ligand-activated PPAR-γ restores phosphorylated Bad and its interaction with 14-3-3ε
The anti-apoptotic action of 14-3-3ε is attributed to binding and sequestering phosphorylated
Bad (p-Bad). To understand how rosiglitazone-PPAR-γ protects against apoptosis via
14-3-3ε, we analyzed p-Bad under OGD stress and determined 14-3-3ε and p-Bad
interaction. p-Bad was detected in control cells which was suppressed by OGD (H3R24) but
was restored partially by rosiglitazone (Fig. 8a). Decline of p-Bad in OGD-treated cells
correlates with that of 14-3-3ε and rosiglitazone restored both proteins in a correlative
fashion (Fig. 8a). Decline of 14-3-3ε and p-Bad by OGD was attenuated by PPAR-γ
overexpression (Fig. 8b). To determine whether rosiglitazone enhances binding of Bad by
14-3-3ε, we prepared cell lysates of OGD-injured N2-A treated with or without
rosiglitazone. The lysate proteins were immunoprecipitated with a 14-3-3ε antibody and
analyzed by Western blotting. In the presence of rosiglitazone, a large quantity of p-Bad and
14-3-3ε proteins were detected in the immunoprecipitate (Fig. 8c) consistent with enhanced
binding of p-Bad to 14-3-3ε by rosiglitazone. To determine whether rosiglitazone and
PPAR-γ attenuate Bad-induced mitochondrial damage, we measured mitochondrial
membrane potential (MMP) by flow cytometry using JC-1 fluorescent probe. OGD (H3R12)
caused a significant reduction of normal MMP cells which was attenuated by rosiglitazone
(Fig. 8d) or PPAR-γ overexpression (Fig. 8e). The protective action of either treatment was
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abrogated by 14-3-3ε siRNA and not control scRNA (Fig. 8d & 8e). Furthermore, 14-3-3ε
overexpression attenuated OGD (H3R12)-induced MMP disruption (Fig. 8f).
Discussion
In this study, we identify a novel transcriptional mechanism by which TZDs such as
rosiglitazone protect against ischemic neuronal apoptosis and cerebral infarction. Our results
provide strong evidence for an essential role of PPAR-γ-mediated 14-3-3ε upregulation in
neural protection. Suppression of PPAR-γ with RNAi or inhibition of PPAR-γ with
pharmacological inhibitors abrogates the protective action of rosiglitazone in vivo and in
vitro. Furthermore, PPAR-γ transfection or infusion of PPAR-γ proteins alone attenuates
neuronal apoptosis and infarct volume in rats while knockin of a PPAR-γ mutant (P465L)
aggravates infarction in mice. These results suggest that PPAR-γ activated by exogenous
ligands such as rosiglitazone or certain endogenous ligands plays an essential role in
protection against ischemic and hypoxic insults. Our data provide strong evidence for direct
activation of 14-3-3ε transcription by PPAR-γ. We show that PPAR-γ binds to PPRE-
harboring region of 14-3-3ε promoter and upregulates 14-3-3ε expression. Importantly,
rosiglitazone restores 14-3-3ε expression in hypoxia-injured cells or brain tissues. Reduction
of 14-3-3ε expression was recently detected by proteomic analysis in neonatal rat hypoxia/
ischemia (20) but to our knowledge has not been reported in ischemic stroke. As reduction
of 14-3-3ε makes the neural tissues vulnerable to damage, restoration of 14-3-3ε by
rosiglitaznoe contributes to its protective action. The effect of rosiglitazone on 14-3-3ε
restoration is PPAR-γ dependent. These results indicate that ligand-activated PPAR-γ drives
14-3-3ε expression and increases cellular 14-3-3ε proteins in normal and ischemic tissues.
Our results further show that the protective actions of rosiglitazone or PPAR-γ
overexpression depend on 14-3-3ε upregulation. Knockdown of 14-3-3ε renders
rosiglitazone or PPAR-γ ineffective in protecting neural tissues whereas 14-3-3ε
overexpression renders cells resistant to apoptosis. Furthermore, direct intraventricular
injection of 14-3-3ε or PPAR-γ proteins attenuates the I/R-induced infarction in a dose-
dependent manner. Intraventricular injection of growth factors, antibodies or inhibitory
peptides was previously shown to control ischemic brain lesions (21,22). It is unclear how
the injected proteins or peptides work. It was proposed that they may enter cells via
endocytosis. Taken together, the results indicate that PPAR-γ mediated 14-3-3ε upregulation
plays a crucial role in protection against neuronal apoptosis and cerebral infarction. This
transcriptional pathway represents a new paradigm of cell and tissue protection.
Recent reports from our laboratory indicate that PPAR-δ ligands protect endothelial cells
and colon cancer cells from apoptosis by inducing PPAR-δ binding to PPRE thereby
enhancing 14-3-3ε proteins and increasing Bad sequestration (18,23). Promoter analysis
reveals that ligand-activated PPAR-δ binds to the similar PPRE region as ligand-activated
PPAR-γ (18). A C/EBP binding site was also implicated in PPAR-δ mediated 14-3-3ε
expression (24). Thus, the protective actions of these two PPAR isoforms are mediated by a
similar transcriptional mechanism. We provide evidence in this study that rosiglitazone
selectively activates PPAR-γ-mediated 14-3-3ε upregulation. It does not induce PAPR-δ
binding to the PPRE sites. It should be important to determine whether PPAR-δ ligands such
as prostacyclin also selectively activate PPAR-δ-mediated 14-3-3ε upregulation. Another
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important issue to be investigated is whether there exists cellular and tissue specificity for
PPAR-γ vs. PPAR-δ mediated 14-3-3ε upregulation by their respective ligands. For
example, it is unclear whether PPAR-γ ligands are capable of protecting endothelial cell
survival via the PPAR-γ→14-3-3ε pathway, nor is it clear whether PPAR-δ ligands protect
against I/R injury via PPAR-δ-mediated 14-3-3ε upregulation. Nevertheless, findings from
this report together with results from previous reports suggest a potential synergistic
interaction between PPAR-γ and PPAR-δ in cytoprotection via similar transcriptional
activation of 14-3-3ε but depends on selective ligands.
14-3-3ε is a member of the 14-3-3 protein family (25), which bind diverse proteins and
functions as a scaffold to facilitate or attenuate the activities of the binding proteins (26).
Recently, 14-3-3 has been shown to co-localize with a variety of specific pathological
deposits, such as neurofibrillary tangles, Pick bodies and Lewy bodies (27). Moreover, up-
regulation of 14-3-3 immunoreactivity was noted in human brain infarction, which was
considered to be involved in post-ischemic cell survival and astrogliosis (28,29). However,
physiological functions or pathological roles of each given 14-3-3 isoform are generally
unknown. In the present study, we identify the 14-3-3ε isoform as an important protector of
brain. 14-3-3 has previously been shown to bind p-Bad, sequesters it in the cytoplasm and
thereby prevents Bad-induced apoptosis via the mitochondrial pathway (30-32). We show in
this study a quantitative correlation between 14-3-3ε proteins and p-Bad and an enhanced
binding of p-Bad by PPAR-γ mediated 14-3-3ε upregulation. Furthermore, elevated 14-3-3ε
contributes to normalization of MMP. Taken together, these results indicate that 14-3-3ε
upregulation by ligand-activated PPAR-γ enhances p-Bad sequestration thereby reducing
Bad translocation to mitochondria to disrupt MMP and induce apoptosis.
Rosiglitazone exerted a dose-related biphasic effect on infarct volume (Fig. 1a). The U-
shaped dose response which was named hormesis has been noted with pharmacologically
active compounds including corticosteroids and receptor agonists (33,34). The underlying
mechanisms for biphasic actions are largely unknown. As we were interested in
understanding how rosiglitazone protects I/R brain injury, we focused in this study on the
concentrations that exert protective actions. It remains unclear why rosiglitazone at high
doses (>300 ng) loses protective effect nor is it known whether at high doses, rosiglitazone
is still active in PPAR-γ-dependent upregulation of 14-3-3ε expression. Further studies are
needed to resolve this complex issue.
In summary, we have discovered a transcriptional pathway that is critical for protection
against neuronal apoptosis and cerebral infarction. PPAR-γ-mediated 14-3-3ε upregulation
represents an important transcription mechanism by which PPAR-γ agonists protect tissues
from I/R injury and is a potential therapeutic target for important human diseases such as
ischemic stroke and myocardial infarction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ischemia-reperfusion (I/R) injury is a major cause of cardiovascular diseases. The
antidiabetic thiazolidinediones (TZD) were reported to protect against I/R injury.
However, the mechanism of actions is unknown. We postulated that TZDs protect against
I/R injury by driving peroxisome proliferatior-activated receptor-γ (PPAR-γ) mediated
gene expression. To test this hypothesis, we evaluated the effect of rosiglitazone on
infract volume in a rat cerebral I/R model. Rosiglitazone reduced infarct volume and
suppressed neural apoptosis in a PPAR-γ dependent manner. Proteomic analysis revealed
elevation of 14-3-3ε in rosiglitazone-treated brain tissues. 14-3-3ε upregulation was
abrogated by PPAR-γ siRNA. Rosilgitazone and PPAR-γ overexpression (Rosi/PPAR-γ)
increased 14-3-3ε promoter activities in a neuronal cell line N2-A. Rosiglitazone induced
PPAR-γ but not PPAR-δ binding to PPAR response elements of 14-3-3ε promoter.
14-3-3ε upregulation plays a crucial role in conferring protection against I/R injury as
knockdown of 14-3-3ε with siRNA abrogated the protective effect of Rosi/PPAR-γ while
injection of 14-3-3ε expression vectors or recombinant proteins rescued tissues from I/R
injury. 14-3-3ε upregulation was accompanied by increased binding and sequestration of
phosphorylated Bad. These results indicate that rosiglitazone protects against I/R injury
by activating PPAR-γ, thereby enhancing 14-3-3ε expression, increasing Bad
sequestration and attenuating Bad-mediated apoptosis. Taken together with recent reports
that prostacyclin inhibits apoptosis by activating PPAR-δ mediated 14-3-3ε upregulation
in cultured endothelial cells, the results indicate that 14-3-3ε upregulation by ligand-
restricted PPAR-γ or PPAR-δ activation represents a novel pathway for cytoprotection
and a target for treating diseases such as ischemic stroke and myocardial infarction.
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Figure 1. Rosiglitazone and PPAR-γ reduce ischemic brain injury in vivo
(a) Rosiglitazone was injected intraventricularly immediately after 30-min ischemia. Infarct
volumes were determined after 24 h reperfusion. (b) Rosiglitazone (50 ng) was infused 2 h
after a 30-min transient occlusion. (c) Rosiglitazone with & without GW9662 was infused.
(d) PPAR-γ siRNA (0.5 nmol) or scRNA (2 nmol) was infused intraventricularly
immediately after ischemia and PPAR-γ mRNA of brain tissues was measured 24 h later.
The upper panel shows a representative gel and the lower panel, mean ± SD of densitometric
analysis of four independent experiments. (e) Rosiglitazone with or without PPAR-γ siRNA
was infused immediately after 30-min ischemia, and infarct volume was measured 24 h
later. (f) Recombinant PPAR-γ protein (5 μg) was infused intraventricularly for 72 h before
a 30-min ischemia. The inset indicates cortical PPAR-γ protein levels at 24 h after
reperfusion. (g) PPAR-γ P465L dominant negative mutant mice (L/+) and wild type
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littermate controls (+/+) were subjected to 30-min ischemia and 24 h reperfusoin. Each bar
denotes mean ± SD (n as indicated). *P<0.05. **P<0.01.
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Figure 2. Analysis of apoptotic signals in ischemic brain
(a) Rosiglitazone (50 ng) or DMSO was injected with PPAR-γ siRNA or control scRNA,
immediately after 30 min ischemia. Active caspases and cleaved PARP were analyzed by
Western blotting. (b) Recombinant PPAR-γ proteins were infused for 72 h before I/R. Left
panels show representative blots and right panels, densitometry of three experiments.
*p<0.05; ** p<0.01.
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Figure 3. 14-3-3ε is increased in rosiglitazone-treated ischemic brain
(a) Rats were subjected to I/R with or without Rosi treatment. Proteins in rat brains were
analyzed with 2-DGE. The insets show a spot with increased density in Rosi-treated vs.
control brain. Analysis by LC-MS/MS identified this spot to be 14-3-3ε. Similar results were
obtained in two other experiments. (b) Western blot analysis of 14-3-3ε in I/R vs. sham.
Rats were treated with rosiglitazone or DMSO immediately after 30-min ischemia. Upper
panel shows a representative blot and the lower panel the error bars from 3 independent
experiments. Each bar denotes mean ± SD. *p<0.05, **p<0.01. (c) 14-3-3ε protein levels in
brain tissues treated with or without rosiglitazone in the presence or absence of PPAR-γ
siRNA or control scRNA. (d) 14-3-3ε proteins in brain tissues treated with recombinant
PPAR-γ proteins or vehicle. (e) 14-3-3ε protein levels in wild-type (+/+) and L/+ mutant
mouse brain tissues. Similar results were obtained in two other experiments.
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Figure 4. Ligand-activated PPAR-γ increases 14-3-3ε transcription
(a-d) 14-3-3ε proteins were analyzed by Western blotting in N2-A cells treated with
rosiglitazone (a), rosiglitazone in the presence of GW9662 (b), rosiglitazone in the presence
of PPAR-γ siRNA or scRNA (c), or PPAR-γ expression vectors (mPPAR-γ) (d). (e) & (f)
N2-A cells transfected with 14-3-3ε promoter constructs p1625 or p1348 were treated with
rosiglitazone (e) or PPAR-γ (f). Promoter activity was expressed as relative light unit (RLU)
using β-gal (b-Gal) as control to normalize the activity. (g) ChIP analysis of PPAR-γ binding
to the PPRE region (upper panel) of 14-3-3ε promoter. Binding of PPAR-β/δ was included
as a control. Each bar represents mean ± SD of at least three independent experiments
conducted in triplicate. *P<0.05. **P<0.01.
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Figure 5. Control of cerebral infarction by 14-3-3ε in vivo
(a) Rosiglitazone with or without 14-3-3ε siRNA or scRNA was injected immediately after
30-min ischemia. Inset shows cortical 14-3-3ε mRNA levels. Similar results were obtained
in two other experiments. (b) His-tagged 14-3-3ε recombinant proteins (5~20 μg) were
infused 72 h before I/R. Inset shows 14-3-3ε and His analyzed by Western blotting. Each bar
denotes mean ± SD. *P<0.05. **P<0.01. Similar results were obtained in two other
experiments.
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Figure 6. Rosiglitazone attenuates N2-A apoptosis in a PPAR-γ dependent manner
(a) Cells were subjected to OGD for 3h followed by reoxygenation for 24 h (H3R24) with or
without rosiglitazone (Rosi) and/or GW9662. Apoptosis was analyzed by flow cytometry.
(b) Cells were treated as a) and active caspase 3, 9 and cleaved PARP were determined by
Western blotting. A representative blot is shown. (c) N2-A cells transfected with PPAR-γ
siRNA or control were subjected to OGD (H3R24) with or without Rosi. (d) Cells
transfected with PPAR-γ plasmids were subjected to H3R24. Upper panels show PPAR-γ
proteins analyzed by Western blotting. Each bar denotes mean ± SD from at least three
independent experiments conducted in triplicate. *P<0.05. **P<0.01.
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Figure 7. Rosiglitazone and PPAR-γ restore 14-3-3ε
(a) N2-A cells were subjected to OGD (H3R24) in the presence or absence Rosi and
GW9662, and protein levels of 14-3-3ε were measured. (b) Cells transfected with PPAR-γ
siRNA or control scRNA were subjected to H3R24 in the presence or absence of Rosi. (c)
Cells transfected with PPAR-γ plasmids were subjected to H3R24. The upper panel shows a
representative blot and the lower panel, the densitometry analysis. (d) & (e) Cells
transfected with 14-3-3ε siRNA or control scRNA were subjected to H3R24 with or without
Rosi (d) or PPAR-γ transfection (e). (f) N2-A transfected with 14-3-3ε plasmids were
subjected to H3R24. Each bar denotes mean ± SD of at least three independent experiments
conducted in triplicate. *P<0.05. **P<0.01.
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Figure 8. Interaction between 14-3-3ε and phosphorylated Bad (p-Bad)
(a) & (b) N2-A cells were subjected to H3R24 in the presence or absence of Rosi (a) or
PPAR-γ (b). 14-3-3ε and p-Bad were analyzed by Western blotting. (c) Cells treated with
H3R24 in the presence or absence of Rosi (R) were lysed and immunoprecipitated with a
14-3-3ε antibody. Proteins in the immunoprecipitate were analyzed by Western blotting
using p-Bad or 14-3-3ε antibodies. Upper panels show representative immunoblots and the
lower panels densitometry analysis. (d) & (e) Cells were transfected with 14-3-3ε siRNA or
control and subjected to H3R12 in the presence or absence of Rosi (d) or PPAR-γ (e). MMP
was analyzed by flow cytometry using JC-1 probe. (f) MMP was measured in cells treated
with H3R12 in the presence or absence of 14-3-3ε plasmids. Each bar represents mean ± SD
of at least three experiments. *P<0.05. **P<0.01.
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